Related Experiment Video

Updated: Apr 30, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Investigation of relationship between IL-6 gene variants and hypertension in Turkish population

Esin Karaman1, Meral Urhan Kucuk2,3, Aysegul Bayramoglu4

  • 1Department of Biology, Science and Art Faculty, Adıyaman University, Adıyaman, Turkey.

Cytotechnology
|May 10, 2014
PubMed

Insights

This study found no significant association between Interleukin-6 (IL-6) gene polymorphisms (-174 G/C and -572 G/C) and hypertension in the Turkish population. Plasma IL-6 and C-reactive protein (CRP) levels were also not linked to these IL-6 gene variants or hypertension risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Immunology

Background:

  • Hypertension (HT) is a major global health concern, increasing the risk of stroke, heart attack, and renal failure.
  • Interleukin-6 (IL-6) and C-reactive protein (CRP) are inflammatory markers potentially implicated in cardiovascular diseases.
  • The IL-6 gene has common polymorphisms (-174 G/C) and rarer ones (-572 G/C) in its promoter region, prompting investigation into their role in HT susceptibility.

Purpose of the Study:

  • To investigate the association between IL-6 gene polymorphisms (-174 G/C and -572 G/C) and hypertension in a Turkish population.
  • To analyze the impact of these IL-6 gene polymorphisms on plasma IL-6 and CRP levels.
  • To determine if IL-6 and CRP levels correlate with hypertension in the studied cohort.

Main Methods:

  • Genotyping of IL-6 -174 G/C (rs 1800795) and -572 G/C (rs1800796) polymorphisms using polymerase chain reaction-restriction fragment length polymorphism.
  • Quantification of plasma IL-6 levels via ELISA.
  • Measurement of plasma CRP levels using automated standard biochemical methods.
  • Comparison of genotype frequencies, allelic frequencies, and plasma biomarker levels between 108 hypertension patients and 111 healthy controls from Adıyaman, Turkey.

Main Results:

  • No statistically significant differences were observed in the frequencies of IL-6 gene -174 G/C and -572 G/C genotypes or alleles between hypertensive patients and healthy controls.
  • Plasma levels of IL-6 and CRP did not show significant associations with the investigated IL-6 gene polymorphisms or hypertension status.
  • The -572 G allele and GG genotype were predominant in the Adıyaman Turkish population, with the CC genotype being very rare, especially in controls.

Conclusions:

  • The IL-6 gene -174 G/C and -572 G/C polymorphisms are not significantly associated with hypertension or altered plasma IL-6 and CRP levels in the Turkish population studied.
  • The study suggests that these specific IL-6 gene variants do not confer susceptibility to hypertension in this demographic.
  • The findings indicate a specific allele frequency distribution for the IL-6 -572 G/C polymorphism within the Adıyaman Turkish population.

Keywords:
CRPHypertensionIL-6 gene polymorphism−174 G/C, −572 G/C gene variants

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
886
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.2K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81